The data by Wolff et al. support a model where IMQ interferes with HH signaling downstream of SMO (Figure 1), suggesting that ADORA agonists may prove beneficial also for SMO-inhibitor resistant and SMO-independent cancer entities. This evidence concerns the gene SMO and cancer.